Skip to main
CARL

Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed Inc (CARL) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Carlsmed is a promising investment opportunity due to its strong clinical data, potential for growth and profitability, and favorable economics of its personalized spine implants. The company's financials are robust, with increasing revenue and a growing base of active surgeons, although competitive risks and delays in hospital adoption may pose a challenge. Overall, the potential for Carlsmed to expand into new markets and launch new products makes it a sound investment option with a positive outlook.

Bears say

Carlsmed is a commercial-stage medical device company that has seen solid growth in recent quarters, however, their financials show a negative year-over-year trend with revenues declining from $5.8 million in 2025 to $5.3 million in 2026. The company's revenue is heavily reliant on physician utilization of its AI-enabled personalized solutions, which may face challenges in adoption and competition from other traditional spine fusion procedures. Additionally, the company's high costs for AI technology and ongoing R&D could lead to significant cash burn in the near future.

Carlsmed Inc (CARL) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Carlsmed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Carlsmed Inc (CARL) Forecast

Analysts have given Carlsmed Inc (CARL) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Carlsmed Inc (CARL) has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Carlsmed Inc (CARL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.